MEDIA

RxCELERATE PRESS RELEASES & ARTICLES

ENDPOINTS NEWS: Forget about greed, President Trump: the villain responsible for high drug prices is inefficiency - by David Grainger
PRESS RELEASE: RxCelerate acquires cutting-edge molecular modelling company Prosarix
PRESS RELEASE: RxCelerate Opens UK-Based Chemistry Operations at the University of Warwick
PRESS RELEASE: RxCelerate acquires The Cambridge Partnership Ltd for £1.45 million as Nick Tait joins as Chief Financial Officer
PRESS RELEASE: RxCelerate acquires specialist bioanalytical CRO Total Scientific Ltd
ENDPOINTS NEWS by John Carroll: After building a rep as an architect of experiments, RxCelerate plants its flag in America
PRESS RELEASE: Leading UK drug developer RxCelerate opens first US base in Boston
PRESS RELEASE: RxCelerate acquires cutting-edge molecular modelling company Prosarix


Cambridge, UK and Cambridge, MA • 5th February 2019, 1pm BST

RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today that it has acquired UK-based molecular modelling company Prosarix.   Originally founded in 2006, Prosarix has built a reputation as one of the leading exponents of molecular modelling, supporting both protein engineering and in silico drug design projects.

“The acquisition of Prosarix beautifully complements our existing drug discovery services, including our medicinal chemistry operations based at University of Warwick” said Dr Nigel Ramsden, Executive Vice President, Chemistry, at RxCelerate.

“Prosarix are already well-known to many of our clients” said Dr Jill Reckless, CEO of RxCelerate. “where they have demonstrated over and over again how their proprietary molecular modelling capabilities can discover better molecules than the competition.  We are delighted to now have the unique expertise as part of RxCelerate Group.”

“We are very excited to have this opportunity to join a rapidly-expanding, global, quality biotech business, with a unique platform to delivering cutting-edge drug discovery and development on an out-sourced basis” said Dr Bill Hamilton, the current Chief Executive at Prosarix, which is currently based just outside Cambridge, UK.

RxCelerate operates a unique model, allowing clients to out-source complete drug discovery and development programs to a team of world-class drug developers obviating the need for internal expertise usually required when out-sourcing to contract research organisations.  Founded in 2012, the company initially built its reputation on the quality of its preclinical models of human diseases, but rapidly expanded to offer a comprehensive, turnkey drug discovery and development solution.

“Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof” said Founder and Chairman, Dr David Grainger.  “Jon Heal and the scientific team at Prosarix are talented modellers, with a proven track-record in molecular design.”

About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in-vivo pharmacology, offering proprietary models of a wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate). Contact our UK headquarters: jill@rxcelerate.com Tel: +44 (0)1223 804240. Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028 

About Prosarix UK Ltd.

Prosarix have been developing and utilising its ProtoDiscovery platform for small molecule design and protein engineering since inception in 2006. Using this technology Prosarix has worked with over 40 companies/organisations, often on multiple projects involving a diverse set of targets and objectives. More recently, Prosarix became a subsidiary of Evolva AG in 2014 before spinning out as an independent company again in 2018.

For more information and contact details, please visit www.prosarix.com or contact Bill Hamilton (bill@rxcelerate.com) Tel: +44 (0)1223 870400.

PRESS RELEASE: RxCelerate Opens UK-Based Chemistry Operations at the University of Warwick


October 31st 2018

CAMBRIDGE, England, October 31, 2018 (Newswire.com) –RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has opened UK-based chemistry operations at The University of Warwick. The new operation will be led by Dr Nigel Ramsden, who joins RxCelerate on a full-time basis as Executive Vice President, Chemistry Operations, working closely with Dr David Fox in the Department of Chemistry at Warwick.

RxCelerate has previously offered small molecule discovery services through a network of expert consultants, collaborators and partnerships with contract research organisations in the UK, US, India and China. The new UK-based operation represents a significant expansion in capacity, but also allows RxCelerate to work on synthetic routes too challenging for out-sourcing.

“Investing in a chemistry operation in the UK compliments our business model,” said Dr Jill Reckless, CEO of RxCelerate. “This capability allows us to offer timely chemical and analytical solutions to our clients where tighter control over experimental execution is required.”

“I am excited by the opportunity to join a rapidly expanding business, with a unique ability to deliver solutions to challenging problems in medicinal chemistry, scale-up synthesis and analytics” said Dr Nigel Ramsden, who earned his stripes as a medicinal chemist during a decade-long stint at GlaxoSmithKline before joining Cellzome, where he was responsible for developing drug discovery pipelines in Alzheimer’s Disease and inflammatory diseases.

Dr David Fox, Associate Professor at the University of Warwick, said, “We have delivered numerous chemical solutions, from chemical probes and clinical candidates to scalable process routes to RxCelerate and its clients over a number of years and are delighted that they have made this investment to expand and develop the relationship further.” Professor Mike Ward, Head of the Department of Chemistry at the University of Warwick, added, “We are delighted to see this new partnership between RxCelerate and Warwick’s chemistry department. Close links between academia and industry are of ever-increasing importance as they allow exciting new science to be translated into real-world impact and benefit to society as quickly and effectively as possible and we look forward to seeing the fruits of this new partnership.”

RxCelerate operates a unique model, allowing clients to out-source complete drug discovery and development programs to a team of world-class drug developers obviating the need for internal expertise usually required when out-sourcing to contract research organisations. Founded in 2012, the company initially built its reputation on the quality of its preclinical models of human diseases, but rapidly expanded to offer a comprehensive, turnkey drug discovery and development solution.

Following the acquisition of Cambridge-based Total Scientific in May this year, RxCelerate gained in-house GxP capabilities, as well as the world’s most extensive commercial Phenome-Wide Association Study (PheWAS) platform.

“Opening a chemistry operation in the UK strengthens further the unique RxCelerate offering,” said Founder and Chairman, Dr David Grainger. “Nigel Ramsden and David Fox are two talented drug discoverers, marrying extensive commercial experience with strong academic chemistry credentials. Together they can tackle any problem, however tough, and deliver high-value solutions to our clients in a timely fashion.”

About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in-vivo pharmacology, offering proprietary models of a wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.comand connect with us on Twitter (@RxCelerate). Contact our UK headquarters: jill@rxcelerate.com Tel: +44 (0)1223 804240. Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028 

About the University of Warwick 

The University of Warwick is consistently ranked in the top 10 universities in the UK every UK newspaper university overall league table, and in the top 100 in the world. It is one of the UK’s leading universities, with an acknowledged reputation for excellence in research, teaching, and innovation alongside pioneering links with business and industry. In the Government’s last Research Excellence Framework announced in late December 2014, an independent panel of experts confirmed Warwick as one of the top Chemistry Departments in the UK ranking it 6th overall for research quality with 98% of its research classified as “world-leading” or “internationally excellent.”

For more information and contact details, please visit www.warwick.ac.uk

About Babraham Research Campus

Babraham Bioscience Technologies Ltd(BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Website: www.babraham.com

For more information, please contact Derek Jones, Chief Executive, Babraham Bioscience Technologies Limited. Email: derek.jones@babraham.co.uk Tel: +44 (0)1223 496262

PRESS RELEASE: RxCelerate acquires The Cambridge Partnership Ltd for £1.45 million as Nick Tait joins as Chief Financial Officer


Cambridge, UK and Cambridge, MA – 8th May 2018, 1pm BST

RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has hired Nick Tait as group Chief Financial Officer and also completed the acquisition of the biotech-specialised accounting and back-office services company, The Cambridge Partnership Ltd.

“I am very excited at the opportunity to join a rapidly-expanding business, with a growing client base on both sides of the Atlantic” said Nick Tait, who has extensive experience in high-growth environments, most recently as Finance Director at Metrion Biosciences, Non-Executive Director at Cambridge Healthcare Research, and advisor to DefiniGEN Ltd.

The Cambridge Partnership was founded in 2013, on the Babraham Research Campus, and provides financial control, accountancy, company secretarial and back-office services to the biotechnology industry.

“The Cambridge Partnership remains the only back-office services company exclusively focused on the biotechnology sector” said Dr Jill Reckless, CEO of RxCelerate. “The demands of early-stage biotech companies, investing their equity capital heavily in R&D often in the absence of revenues, requires a unique understanding of the opportunities and challenges that represents. We are delighted to now be able to support The Cambridge Partnership, as part of RxCelerate group, in providing that service to an even larger number of biotech companies in the UK.”

Dr Elaine McKilligin, Founder and Chief Executive at The Cambridge Partnership, said “The rapid growth in demand for our services is exciting. Becoming part of the RxCelerate group will allow us to scale up more rapidly to meet that demand.”

The Cambridge Partnership Ltd will remain as a separate company and brand. Existing clients will be contacted directly, but will see no changes in the services they receive as a result of the change in ownership. RxCelerate will pay up to £1.45million, including an upfront payment of £1.35million to acquire full ownership of the business. No further financial details have been disclosed.

“The RxCelerate vision has always been to provide everything needed to create and run a virtual biotech company” said Founder and Chairman, Dr David Grainger. “These young start-ups need tailored back-office services to free up founders to focus their attention on developing their drug candidates, knowing the administration is being handled properly. The Cambridge Partnership is the only service provider exclusively focused on these biotech start-ups, and we are delighted to have found the next piece of the RxCelerate jigsaw puzzle.”

Last week, RxCelerate announced the acquisition of specialist bioanalytical contract research lab, Total Scientific. These acquisitions bring the total number of employees across the RxCelerate group to 38.

NOTES FOR EDITORS

About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate).

Contact our UK headquarters: caroline@rxcelerate.com Tel: +44 (0)1223 839557.

Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028


About The Cambridge Partnership

The Cambridge Partnership is a specialist provider of accountancy, financial control, company secretarial and corporate governance services exclusively tailored to the needs of small and medium-sized biotechnology companies. It was founded in Cambridge UK in 2013, to fill a gap in the market of support services for R&D-intensive start-up companies. In addition, it provides a one-stop solution to establish new companies, which can be fully operational in as little as four weeks. It also offers bespoke pay-monthly management packages, that ensure compliance with up-to-date legislation on pensions, anti-bribery provisions, data security, company law and other regulatory and compliance matters that typically challenge young companies, while providing day-to-day financial and budget control.

For more information, please visit thecambridgepartnership.com


About Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus.  The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation.  The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Website: www.babraham.com

For more information, please contact:

Derek Jones, Chief Executive, Babraham Bioscience Technologies Limited.

Email: derek.jones@babraham.co.uk   Tel: +44 (0)1223 496262

PRESS RELEASE: RxCelerate acquires specialist bioanalytical CRO Total Scientific Ltd

The out-sourced drug development company, RxCelerate Ltd, announced today that it has completed the acquisition of Cambridge-based specialist bioanalytical contract research organisation, Total Scientific Ltd.

RxCelerate, which has offices in Cambridge, MA and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible.

Total Scientific was founded in 2006, on the Babraham Research Campus, and specialises in measuring complex drugs and proteins in biological samples, compliant with Good Laboratory Practice (GLP).

“Total Scientific was the first company in the world to offer Phenome-wide Association Studies (PheWAS) as a commercial service, underpinning their status as global leaders in highly specialised bioanalysis” said Dr Jill Reckless, CEO of RxCelerate. “This capability, coupled with their GLP-compliant bioanalysis platform significantly extends the range of cutting-edge capabilities available to our clients to move their projects more efficiently to the next value inflection point.”

Dr David Mosedale, Founder and Chief Scientist at Total Scientific, said “We built a fantastic team at Total Scientific over the last ten years, who have solved many challenging problems for our clients. But the opportunity to become part of the RxCelerate group with their global reach into US markets, allowing even more drug developers to benefit from services like PheWAS, which we have pioneered, was simply too good to pass up.”

Total Scientific currently has 11 employees, bringing the total staff at RxCelerate to 37. The Total Scientific brand will be retired with immediate effect, with all services continuing to be offered through RxCelerate. Existing clients will be contacted directly, but will see no changes in the delivery of their projects during the transition. No financial details of the transaction have been released.

“RxCelerate is one of the fastest growing companies in the UK” said Founder and Chairman, Dr David Grainger. “Adding the unique capabilities of Total Scientific to the platform will further cement our reputation as a global leader in out-sourced drug development.”

 

NOTES FOR EDITORS

About RxCelerate

RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services in the United Kingdom. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate).

Contact our UK headquarters: caroline@rxcelerate.com Tel: +44 (0)1223 839557.

Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028


About Babraham Research Campus

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus.  The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation.  The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Website: www.babraham.com

For more information, please contact:

Derek Jones, Chief Executive, Babraham Bioscience Technologies Limited.

Email: derek.jones@babraham.co.uk   Tel: +44 (0)1223 496262

PRESS RELEASE: Leading UK drug developer RxCelerate opens first US base in Boston

RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has hired Laura Hamilton as Executive Vice President, US Operations and opened an office in Cambridge, MA, just outside Boston. “We are bringing RxCelerate’s unique model for out-sourced drug discovery and development to the heart of the largest and most vibrant life sciences cluster on the planet” said Jill Reckless, CEO of RxCelerate.

RxCelerate offers a fully integrated discovery and development service to the pharma and biotech industry, ranging from medicinal chemistry, antibody discovery, preclinical safety and efficacy through to clinical proof of concept. “Contract Research Organisations often provide an excellent way of increasing capacity, acting as extra pairs of hands to perform experiments you design with them” said David Grainger, Executive Chairman at RxCelerate, “but RxCelerate is different. We are architects of drug discovery and development, rather than builders. Our clients need provide nothing more than the target they are interested in, and RxCelerate will deliver a pharma-grade product candidate and progress it into the clinic.”

Founded in 2012 in Cambridge, UK, the RxCelerate team has quickly grown to more than 40 experienced scientists. Clients range from entirely virtual start-ups, using RxCelerate as their infrastructure, through to three of the top fifteen global pharmaceutical companies. “With our home in Europe’s largest bioscience cluster, establishing a base in the epicenter of American biotech seemed to be the logical next step. We already have a number of US clients, but this new move brings us right to their doorstep” said Dr Reckless.

“As the Massachusetts life sciences cluster keeps growing, led by the cutting-edge research at our world-class hospitals and universities, the demand for out-sourced drug discovery and development platforms continues to increase,” said Robert K. Coughlin, President & CEO of Massachusetts Biotechnology Council (MassBio). “I’m confident that RxCelerate will help fill an important role in our state’s biopharma ecosystem.”

There is huge demand for drug discovery and development services in the greater Boston area, and I look forward to introducing many more companies to the unique RxCelerate approach
Laura HamiltonRxCelerate Inc

 

US operations will be led by Laura Hamilton, who has joined RxCelerate from the local industry trade association, MassBio: “There is huge demand for drug discovery and development services in the greater Boston area, and I look forward to introducing many more companies to the unique RxCelerate approach. I am certain RxCelerate can be as successful in Cambridge, MA, as they have been in Cambridge, UK.”

With Department for International Trade (DIT) support over the last two years, RxCelerate began to develop their international trade strategy and looked to expand their business abroad. DIT International Trade Advisers provided the company with local market insights, advice on export strategy and connected them to key target companies in the US, leading to a significant increase in export business in 2017, underpinning the opening of the US office.

Baroness Rona Fairhead, Minister of State for Trade and Export Promotion, said: “We are delighted to support an exciting UK-grown biotech company as it takes its first steps into new markets. The goal of our department is to support UK companies, large and small, sell ever-more of their products and services overseas. RxCelerate is a great example of what can be achieved by a UK company taking advantage of global demand.”

RxCelerate are headquartered on the Babraham Research Campus, home to more than 30 life science companies. “We are deeply integrated into the life sciences ecosystem. With our new US base, that ecosystem just got a whole lot bigger” said Dr Grainger.

Menu